Black Diamond Therapeutics

Black Diamond Therapeutics, Inc. is a leading, venture-backed biotechnology company dedicated to the discovery and development of precision oncology medicines targeting novel allosteric mutant oncogenes. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, is designed to enable Black Diamond to analyze population-level genomic sequencing data to identify oncogenic mutations that drive cancers across multiple tumor types, group these mutations into families, and develop single small molecule therapies that target a specific mutation family in a tumor-agnostic manner.